|
| Study | type | n | Age(y) | Severity | Route | Donor | Fresh/Frozen | Clinical response | Clinical remission | Follow-up (months) |
|
| Angelberger et al [18] (2013) | UC | 5 | 22-51 | moderate-severe | nasojejunal tube and enema | identified but first degree relatives excluded | Fresh | 1 | 0 | 3 |
| Kunde et al [19].(2013) | UC | 10 | 7-21 | mild-moderate | colonoscopy | family members or close friends | Fresh | 6 | 3 | 1 |
| Kump et al [20].(2013) | UC | 6 | 17-52 | moderate-severe | enema | unrelated | Frozen | 2 | 0 | 3 |
| Cui et al [21] a (2015) | UC | 15 | 11-48 | moderate-severe | gastroscope | healthy children (patient relatives or friends) | Frozen | 12 | 4 | 4-72 |
| Damman et al [22] (2015) | UC | 7 | 27-61 | mild-moderate | colonoscopy | family members or close friends | Fresh | 1 | 1 | 3 |
| Ren et al [23] (2015) | UC | 7 | 17-66 | severe | Colonoscopy and gastroscopy | family members or unrelated | Fresh | 7 | 7 | 1-7 |
| Scaldaferri et al [24].(2015) | UC | 8 | 30-44 | mild-moderate | colonoscopy | unrelated | NR | 4 | 3 | 3 |
| Wei al et [25] a(2015) | UC/CD | 14 | 16-70 | mild-moderate | | unrelated | Frozen | 9 | 6 | 1 |
| Suskind et al [26] a.(2015) | UC | 4 | 13-16 | mild-moderate | nasogastric | NR | Fresh | 0 | 0 | 3 |
| Vermeire et al [27].(2016) | UC/CD | 14(8/6) | 28-53 | moderate-severe, refractory, failed immunotherapy and anti-TNF | Nasojejunal or rectal | family members or close friends | Fresh | 2 | 2 | 2 |
| Nishida et al [28].(2017) | UC | 41 | | mild-moderate | colonoscopy | family members | Fresh | 11 | 0 | 2 |
| Wei et al [29] b (2016) | UC | 20 | 18-70 | mild-moderate | colonoscopy | unrelated | Fresh | 13 | 7 | 3 |
| Ishikawa et al [30] (2017) | UC | 17 | 21-65 | mild-to-severe active | colonoscopy | family members | Fresh | 14 | 9 | 1 |
| Zhang et al [31] (2016) | UC | 19 | 19-60 | moderate-severe | gastroscope | NR | Fresh | 11 | 2 | ≥3 |
| Karakan et al [32].(2016) | UC | 14 | NR | Steroid-dependent | colonoscopy | NR | NR | 11 | 6 | 3-18 |
| Goyal et al [33].(2016) | UC/CD | 16(12/4) | <18 | mild-moderate | gastroscope | NR | Fresh | 5 | 2 | 6 |
| Kellermayer et al [34] (2015) | UC | 3 | 14-16 | immunotherapy dependent | colonoscopy and enema | unrelated | Frozen | 3 | 3 | 3 |
| Karolewska-Bochenek et al [35] (2015) | UC | 4 | 10-17 | mild-moderate | gastroscope | unrelated | NR | 4 | 0 | 1 |
| Cui et al [36] b.(2015) | CD | 30 | 15-71 | moderate-severe | gastroscope | family members or close friends or unrelated | 23 Fresh 7 Frozen | 20 | 18 | 6-15 |
| Suskind et al [37] b (2015) | CD | 9 | 12-19 | mild-moderate | nasogastric | family members(parents) | Fresh | 7 | 5 | 3 |
| Vaughn et al [38].(2016) | CD | 19 | | active | colonoscopy | unrelated | | 11 | 10 | 6.5 |
| Zhang et al [39].(2013) | CD | 16 | 14-63 | refractory | gastroscope | NR | Frozen | 12 | 3 | 1 |
| Alka-Goyal etal [40],(2018) | UC/CD | 21(14/7) | 8-21 | refractory | colonoscopy and gastroscopy | family members or close friends | Fresh | 6 | 2 | 6 |
|
